MonobodyBased Therapeutic Drugs Market - Global Industry Insights, Trends, Outlook,and Opportunity Analysis, 2018-2026
Monobodies are synthetic bindingproteins in which fibronectin type III domain (FN3) is used as a molecularscaffold. Monobodies are robust alternative to antibodies to createtarget-binding proteins. The term monobody was devised by Koide group in 1998.Monobody belong to a class called antibody mimics aiming to overcome theshortcomings of natural antibody. A major advantage of monobody is that it canbe used as genetically encoded intracellular inhibitors. Adnexus (now a part ofBristol-Myers Squibb), uses monobody technology to inhibit tumor angiogenesissince 2007.
Monobody – a technology with greatpotential in Cancer Treatment
Monobody is a technology whichhas great potential in the treatment of cancer. Monobody is independent oftheir environment and can be used as genetically encoded inhibitors. When amonobody binds to a protein then it work as an inhibitor of that protein.
Pegdinetanib, also known asAdnectin, is an antagonist of vascular endothelial growth factor receptor 2 hasentered in clinical trial II for the treatment of glioblastoma. Adnectins isbased on 10th fibronectin type III domain designed to bind with high affinityand specificity to relevant targets. There are three solvent accessible loops(BC, DE, and FG) which are responsible for binding. Various monobody proteinshave been developed for clinical efficacy against cancer and infections. The market of monobody will be high indeveloped region like America because of availability of advance medicaltechnology, good medical facilities and medical infrastructure.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/43
Success of therapeutic antibodieshas sparked a growing interest to create molecules that bind to the targetmolecule specifically and efficiently. A common alternative process is that thelibraries of monobody being constructed which can be obtained by capturing naturaldiversity of an antibody.
Research in the field of Monobody
Researchers at the University ofIllinois, Chicago identified a monobody, NS1, which can block oncogeneactivity. 30% of all cancers are due to RAS mutation. RAS mutation is alsofound in 90% of pancreatic cancers and frequently occurs in colon cancer, lungcancer and melanoma. The NS1 monobody bind to RAS protein molecule and inhibitsits oncogenic activity.
Monobody – a better alternative
Antibodies are successful toolsused in diagnostics, purification, and therapeutics. Antibodies have theirlimitations also like high product cost and low stability. Alternative toolsbased on nucleic acid (aptamers), polypeptides (engineered binding proteins)and inorganic matrices have received attention recently. With increasingresearch activities for drug development in cancer, more information would begathered with respect to monobodies too. Because of high specificity andaffinity monobodies have potential and can be used in organ transplant in nearfuture and can affect the antibodies market. Successful outcomes will boostinvestors to develop this technology and address the unmet need of cancerpatients undergoing antibody therapy. Use of monobodies as therapeutic drugimproves patient situation and hence companies are striving to developmonobodies to be used as therapeutic drugs in the treatment of cancer.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/monobody-based-therapeutic-drugs-market-43
Introduction of monobody willhave a major impact in developed regions
The rate of organ transplantationin the U.S. is high. According to National Kidney Foundation, there arecurrently 121,678 people waiting for organ transplant in the U.S of which100,791 await kidney transplant. Monoclonal antibodies are used in successfultransplant and are administered before transplant. It will become one of themajor drivers for monobody based therapeutic drugs market. Monobody technologyrequires high investment to commercialize. The advancement of monobodytechnology to treat cancer will have an impact on the existing antibodytreatment technologies.
Key Developments
Research and development in useof monobody-based therapies is expected to boost the market growth. Forinstance, in August 2019, researchers from The University of Chicagocharacterized 42 Flublok-induced monoclonal antibodiesand 38 Flucelvax-inducedmAbs for avidity, cross reactivity, and any selectivity towards the head versusthe stalk domain to compare the fine specificity of the antibodies induced by recombinanthemagglutinin vaccine produced in insect cells (Flublok) and Flucelvax,prepared from virions produced in mammalian cells.
Similarly, in August 2019,researchers from Icahn School of Medicine at Mount Sinai characterizedmonoclonal antibodies isolated from a patient with an active Zika virusinfection that potently neutralized virus infection in Vero cells at thenanogram-per-milliliter range.
In June 2018, researchers fromBristol-Myers Squibb reported that 6200_A08, a novel gp41-binding Adnectin withpotent anti-HIV activity is highly synergistic when linked to a CD4-bindingAdnectin. Novel bispecific molecules of this type may serve as the nextgeneration of potent antiviral agents.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/43
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
